Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 1/20 | 0.57 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.57 |
| ▸ | DNA2 | P51530 | 1/20 | 0.54 |
| ▸ | CASP6 | P55212 | 1/20 | 0.54 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.54 |
| ▸ | ERN1 | O75460 | 1/20 | 0.50 |
| ▸ | PIM1 | P11309 | 6/20 | 0.49 |
| ▸ | PIM3 | Q86V86 | 6/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.48 |
| ▸ | CLK1 | P49759 | 2/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27566405 | 0.86 | DNA2 (0.52) | TRIM24TRIM33DNA2CASP6CTDSP1 | |
| SCHEMBL13342691 | 0.84 | TRIM24 (0.57) | TRIM24TRIM33DNA2CASP6CTDSP1 | |
| SCHEMBL19651761 | 0.83 | DNA2 (0.50) | TRIM24TRIM33DNA2CASP6CTDSP1 | |
| SCHEMBL30946589 | 0.82 | DNA2 (0.52) | DNA2CASP6CTDSP1TDP1CLK1 | |
| SCHEMBL27174903 | 0.82 | DNA2 (0.52) | DNA2CASP6CTDSP1TDP1CLK1 | |
| SCHEMBL27174908 | 0.82 | DNA2 (0.52) | DNA2CASP6CTDSP1TDP1CLK1 | |
| SCHEMBL7661967 | 0.78 | TRIM24 (0.50) | TRIM24TRIM33ERN1PIM1PIM3 | |
| SCHEMBL27577619 | 0.77 | DNA2 (0.50) | DNA2CASP6CTDSP1ERN1TDP1 | |
| SCHEMBL29954763 | 0.77 | TRIM24 (0.70) | TRIM24TRIM33PIM1PIM3TDP1 | |
| SCHEMBL1017079 | 0.77 | DNA2 (0.56) | DNA2CASP6CTDSP1TDP1CLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634155-A1 | RBM39 SULFONAMIDE INHIBITORS | Recursion Pharmaceuticals, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4573088-A1 | HETEROCYCLE RBM39 MODULATORS | Recursion Pharmaceuticals, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| CN-119630658-A | Heterocyclic RBM39 modulators | 递归医药公司 | 2025-03-14 | — | — | CN | disclosed |
| WO-2024129634-A1 | RBM39 SULFONAMIDE INHIBITORS | RECURSION PHARMACEUTICALS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240092770-A1 | Heterocycle RMB39 Modulators | RECURSION PHARMACEUTICALS, INC. | 2024-03-21 | — | — | US | disclosed |
| WO-2024039689-A1 | HETEROCYCLE RBM39 MODULATORS | RECURSION PHARMACEUTICALS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| CN-115785079-B | 4- (1H-indol-5-yl) aminofuran-2 (5H) -ketone compound, and preparation and application thereof | 沈阳药科大学 | 2024-02-13 | — | — | CN | disclosed |
| CN-110526854-B | Alpha, beta-unsaturated ketone derivative, preparation method and application thereof as medicine | 宁夏医科大学 | 2023-12-15 | — | — | CN | disclosed |
| CN-115785079-A | 4- (1H-indole-5-yl) amino furan-2 (5H) -ketone compound and preparation and application thereof | 沈阳药科大学 | 2023-03-14 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-1294716-A1 | LACTAM INHIBITORS OF FACTOR XA AND METHOD | Bristol-Myers Squibb Company (US) | 2003-03-26 | — | — | EP | disclosed |
| EP-1258252-A1 | INTEGRIN EXPRESSION INHIBITORS | Eisai Co., Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
| US-20020025957-A1 | Lactam inhibitors of factor Xa and method | BRISTOL-MYERS SQUIBB COMPANY | 2002-02-28 | — | — | US | disclosed |
| WO-2001096331-A1 | LACTAM INHIBITORS OF FACTOR XA AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| EP-0680950-B1 | PROPENONE DERIVATIVES | KYOWA HAKKO KOGYO KK (JP) | 2001-05-23 | — | — | EP | disclosed |
| US-5952355-A | 1-ETHER-SUBSTITUTED PHENYL-3-INDOL-3-YL-2-PROPEN-1-ONE DERIVATIVES; ANTITUMOR AND -CARCINOGENIC AGENTS; IMMUNOSUPPRESSANTS; AUTOIMMUNE DISEASES; SIDE EFFECT REDUCTION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1999-09-14 | — | — | US | disclosed |
| US-5767283-A | CHEMICAL INTERMEDIATE FOR 7-N-ORGANOSULFONYL-1H-INDOLE DERIVATIVE ANTITUMOR AGENTS; NONTOXIC | EISAI CO., LTD. (JP) | 1998-06-16 | — | — | US | disclosed |
| US-5721246-A | ANTITUMOR AGENTS; LOW TOXICITY | EISAI CO., LTD. (JP) | 1998-02-24 | — | — | US | disclosed |
| EP-0680950-A1 | PROPENONE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1995-11-08 | — | — | EP | disclosed |
| EP-0673937-A1 | BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES | Eisai Co., Ltd. (JP) | 1995-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092770-A1 | Heterocycle RMB39 Modulators | PRMT9, RCC2, RBBP9 | TRIM24 1156/4885TRIM33 2758/4885DNA2 871/4885 |
| US-20020025957-A1 | Lactam inhibitors of factor Xa and method | F9, F7, F11 | TRIM24 2533/4885TRIM33 4517/4885DNA2 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.